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Abstract
Objective: The objective of this article is to investigate potential clinical and MRI predictors of long-
term outcomes in multiple sclerosis (MS).
Methods: This was a post hoc analysis using data from all 382 patients in the PRISMS long-term
follow-up (LTFU) study collected up to eight years after randomisation. An additional analysis was
performed including only those patients originally randomised to receive early subcutaneous interferon
(IFN) b-1a (n¼ 259). Baseline/prestudy variables, indicators of early clinical and MRI activity (baseline
to month 24), and indicators of IFN b-1a treatment exposure (including medication possession ratio
(MPR)) were investigated as candidate prognostic factors for outcomes measured from baseline and
from month 24 to LTFU. Explanatory variables identified from univariate regression models (p 0.15)
were selected for inclusion in stepwise multiple regression models.
Results: Candidate prognostic factors selected by the univariate analysis (p 0.15) included age, MS
duration, baseline brain volume, EDSS score, and log(T2 burden of disease (BOD)). In most of the
multivariate regression models applied, higher baseline brain volume and MPR predicted better long-
term clinical outcomes, while higher baseline and greater early increase in EDSS score predicted worse
outcomes.
Conclusion: Identification of markers that may be prognostic for long-term disability could help identify
MS patients at higher risk of disability progression.
Keywords: Disability, follow up, long-term outcomes, MRI, multiple sclerosis, prognosis
Date received: 18 January 2016; accepted: 5 August 2016
Introduction
Multiple sclerosis (MS) is a chronic, lifelong disease
that has a highly variable course which can cause
severe disability over time in many patients.
Therefore, early determination of clinical, magnetic
resonance imaging (MRI), and/or biological markers
that are prognostic for long-term outcomes would be
valuable, to enable management strategies tailored to
the needs of individual patients.1 Currently, no base-
line or short-term clinical or MRI measures have
proven to be consistent prognostic factors.2,3
The Prevention of Relapses with Interferon beta-1a
Subcutaneously in Multiple Sclerosis (PRISMS)
study demonstrated the efficacy of interferon (IFN)
b-1a, 44 and 22 mg administered subcutaneously (sc)
three times weekly (tiw), compared with placebo,
in reducing relapses, MRI lesion activity and accu-
mulation, and in preventing disability in patients
with relapsingremitting MS (RRMS).4 This popu-
lation was followed for up to eight years from ran-
domisation,5,6 with a 77% patient retention rate for
sites that participated in the long-term follow-up
(LTFU) visit, thus providing a useful cohort within
which early clinical and MRI variables could be
analysed as predictors for long-term disease status.
Long-term outcomes were determined seven to eight
years after the start of the original randomised clin-
ical trial. The objective of this post hoc analysis of
the PRISMS LTFU data set was to determine
whether prestudy and baseline characteristics,
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indicators of early MRI and clinical activity, and
indicators of treatment exposure could be identified
as prognostic factors of long-term clinical and MRI
outcomes in patients with RRMS.
Methods
Patients and study design
All patients (N¼ 560) who had undergone random-
isation in the PRISMS study were eligible for enrol-
ment into the LTFU study (protocol number 22930),
regardless of when their participation in the original
study had been terminated.
PRISMS was a randomised, double-blind trial that
compared IFN b-1a (44 and 22 mg sc tiw) with pla-
cebo, for two years. The study was extended for two
additional years (years 34), during which patients
originally randomised to placebo were re-rando-
mised to one of the two doses of sc IFN b-1a
(Figure 1). Patients who completed the four-year
study were then given the opportunity to continue
on blinded or open-label treatment (44 or 22 mg sc
tiw) for the following two years (i.e. up to year 6).
Between withdrawal from, or completion of,
six years on study, and up to and including the
LTFU assessment, patients could take any or no dis-
ease-modifying drug (DMD) for MS. The trial fin-
ished at year 6 and the LTFU consisted of a single
visit seven to eight years following original
randomisation.46
Standard protocol approvals, registrations, and
patient consents
Local ethical and health authority approval was
required for participation at LTFU, and all patients
gave written informed consent in accordance with
the Declaration of Helsinki.
Assessments
During the PRISMS study, neurological assessments
were performed every three months over years 1 to 3,
and then every six months over years 4 to 6. At the
LTFU assessment, patients underwent a neurological
evaluation to determine their current Expanded
Disability Status Scale (EDSS) score and whether
they had developed secondary progressive MS
Figure 1. PRISMS study design and LTFU analysis sets.
Early-start patients received treatment from baseline of the current study. Patients with delayed-start treat-
ment received IFN b-1a after a period of two years. IFN: interferon; LTFU: long-term follow-up; PRISMS:
Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis; sc: sub-
cutaneously; tiw: three times weekly.
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(SPMS; defined as progressive deterioration of dis-
ability for 12 months and a deterioration in EDSS
score of 1 point (or 0.5 points between EDSS
scores 6.0 and 6.5) not associated with an exacerba-
tion, following an initial relapsingremitting
course). A non-contrast proton-density/T2-weighted
brain MRI scan was performed every six or
12 months during the original PRISMS study and
extension study, respectively, and again at the
LTFU visit using the same imaging protocol.
New T2 activity was defined as new or enlarging
T2 lesions compared with a previous MRI scan.
T2 burden of disease (BOD) was defined as the
summed cross-sectional area (in mm2) of lesions
on T2 scans. Brain volume was assessed using the
brain parenchymal ratio, which was derived by sub-
tracting cerebral spinal fluid (CSF) from intradural
volume and normalising to the whole brain volume.
Post hoc analysis
This post hoc exploratory analysis was performed in
all LTFU patients (n¼ 382) and in the subcohort
originally randomised to sc IFN b-1a (early-start
patients, n¼ 259) (Figure 1).
Outcome and explanatory prognostic variables
The long-term outcome variables for which prognos-
tic factors were sought were: change in EDSS score,
EDSS progression, time to first EDSS progression,
EDSS score 6, time to EDSS score 6, conversion
to SPMS, time to conversion to SPMS (calculated as
the number of days between study day 1 of the ori-
ginal PRISMS study and the date on which SPMS
conversion was observed), negative disability out-
come (NDO; EDSS score 6 and/or SPMS), time
to negative disability outcome, change in log(T2
BOD), and percentage change in brain volume
(change in brain volume was measured from baseline
to LTFU only).
The baseline/prestudy explanatory variables investi-
gated as candidate prognostic factors were: age, sex,
duration of MS, prestudy annualised relapse rate
(ARR; during the two years prior to baseline),
EDSS score, log(T2 BOD), and brain volume.
Explanatory variables were investigated as candidate
prognostic factors for outcomes measured from base-
line to LTFU and from month 24 to LTFU. Some
potential predictors might have changed within the
first 24 months of the PRISMS study. Thus, the
month 24 to LTFU analysis was conducted to
account for potential cases of an outcome occurring
before a predictor.
The indicators of early clinical or MRI activity from
baseline to month 24 that were investigated as can-
didate prognostic factors were: ARR, EDSS progres-
sion, number of EDSS progressions, change in EDSS
score, number of new or enlarging T2 lesions,
number of active T2 scans (showing at least one
new or enlarging T2 lesion), change in log(T2
BOD), and T2 composite score (measured at
months 12 and 24; missing values were imputed by
the last observation carried forward (LOCF)
approach; details on the T2 composite score are
given below).
EDSS progression was defined as an increase in
EDSS score by 1 point if the score was <6 at base-
line or the last visit, or otherwise by 0.5 points,
confirmed after three months. Long-term clinical
outcome variables also included a combined nega-
tive disability outcome, which was defined as an
EDSS score 6 and/or SPMS. Outcome variables
and explanatory variables that were related to T2
BOD used the logarithm of T2 BOD to normalise
this measurement, which tends to be skewed.
A T2 composite score was created to combine and
categorise the two T2 lesion-related variables: active
T2 lesion number and T2 BOD change. The score is
the sum of a three-point score for the number of
active T2 lesions between baseline and months 12
or 24 (0 points: 6 lesions; 1 point: 720 lesions;
2 points: >20 lesions), and a 3-point score for T2
BOD change from baseline to months 12 or 24
(0 points: change700mm2; 1 point: change
>700 and þ300mm2; 2 points: chan-
ge>þ300mm2), yielding a composite score of
04 points.
Indicators of IFN b-1a treatment exposure that were
investigated as candidate prognostic factors were:
medication possession ratio (MPR; calculated as
100 time (days) on sc IFN b-1a treatment from
baseline to LTFU visit/time (days) from baseline to
LTFU visit); IFN b-1a early or delayed start status
(all-patients analysis only); and IFN b-1a high
(44 mg) or low (22 mg) dose (early-start IFN b-1a
patients analysis only).
Regression analyses
Stage 1 of the post hoc analysis used univariate
regression models to identify explanatory variables
(p> 0.15) for further evaluation using multivariate
regression analysis (Stage 2). This conservative
cutoff (p> 0.15) was selected to ensure that poten-
tial prognostic factors were not prematurely
discarded. Correlation analysis of explanatory
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variables was also carried out; if a pair of explana-
tory variables had a Spearman rank correlation coef-
ficient (r) 0.7 or0.7, only one of the two
variables was selected to avoid problems with
multicollinearity.
At Stage 2, the selected explanatory variables were
fitted in final stepwise multivariate regression
models using multiple linear regression for continu-
ous or ordinal outcomes, logistic regression for
binary outcomes, and Cox proportional hazards
model for time-to-event outcomes.
Results
Patients
A total of 382 patients participated in the LTFU visit
(Figure 1), representing 77% (382/493) of patients
originally randomised in the PRISMS study at sites
which participated in the LTFU visit (of the original
participating centres, three did not participate in the
LTFU study for administrative reasons not related to
the outcomes). Of the returning patients, 72% (275/
382) were still receiving sc IFN b-1a at LTFU (160
receiving 44 mg tiw and 115 receiving 22 mg tiw).
Descriptive statistics
Prestudy and baseline characteristics were similar in
the two LTFU analysis sets (all patients and early-
start IFN b-1a patients), except for slightly longer
mean (SD) disease duration in the early-start
patients: 7.97 (6.14) years, compared with 7.35
(5.81) years in all patients. The median time to
EDSS progression was also longer in early-start
patients compared with all patients (6.54 vs 5.80
years). In keeping with the beneficial therapeutic
effect, indicators of clinical and MRI activity from
baseline to month 24 were also more favourable in
early-start patients compared with the all-patients
group: a smaller percentage of patients with EDSS
progression (27.8% vs 31.7%), a smaller increase in
log(T2 BOD) (mean (SD) changeþ 0.01 (0.46)
vsþ 0.05 (0.44)), and fewer new or enlarging lesions
at month 24 (mean (SD) 1.30 (2.73) vs 1.91 (3.15)).
Prestudy and baseline characteristics are shown in
Table 1; indicators of early disease activity for
these two patient groups are available in Table e-1.
Univariate explanatory variables for
LTFU outcomes
All patients. Age, duration of MS, baseline EDSS
score, baseline log(T2 BOD), and baseline brain
volume were variables with p 0.15 for most long-
term outcomes, both for outcomes measured from
baseline to LTFU (Table e-2) and outcomes mea-
sured from month 24 to LTFU (data not shown).
Sex did not reach a p 0.15 for any long-term out-
come and was therefore not selected for the multi-
variate analysis. Explanatory variables which
fulfilled the p 0.15 criterion included only three
outcomes (change in EDSS score, time to EDSS pro-
gression, change in brain volume) measured from
baseline to LTFU (Table e-2), and for only one out-
come (time to EDSS progression) measured from
month 24 to LTFU.
EDSS progression, number of EDSS progressions,
and change in EDSS from baseline to month 24
were associated with all clinical outcomes measured
from baseline to LTFU (Table e-3) and for the
majority of outcomes from month 24 to LTFU
(data not shown). ARR during the first two years
was associated with change only in log(T2 BOD)
measured from month 24 to LTFU.
T2 composite scores at months 12, 24, and 24 LOCF
were associated with the largest number of long-term
clinical and MRI outcomes measured from baseline
to LTFU (Table e-3) and from month 24 to LTFU.
Early MRI activity fulfilled the cutoff criterion both
for change in log(T2 BOD) and change in brain
volume from baseline to LTFU but not for clinical
outcomes (Table e-3).
Mean (SD) MPR was 78.0% (26.7%) and MPR was
associated with the majority of long-term clinical
and MRI outcomes measured from baseline to
LTFU (Table e-3).
Simple Pearson correlation coefficients for explana-
tory variables with p 0.15 varied depending on the
final clinical or MRI outcome, and generally ranged
from 0.1 to 0.5. Medium strength baseline explanatory
variables for later clinical outcomes were EDSS score
(r¼ 0.51 for EDSS 6; r¼ 0.39 for SPMS). Further
explanatory variables were duration of MS (r¼ 0.15
for EDSS 6; r¼ 0.14 for NDO); baseline log(T2
BOD) (r¼ 0.160.22), and baseline brain volume
(r¼ 0.210.33). At month 12, the T2 composite
score showed correlations with change in EDSS
(r¼ 0.20) and EDSS score 6 (r¼ 0.13). Other
explanatory variables at month 24 were ARR
(r¼ 0.16 for change in EDSS to LTFU; r¼ 0.14 for
EDSS progression) and change in EDSS score from
baseline to month 24, which gave r values between
0.33 and 0.55 for all clinical outcomes.
Early-start patients. Results similar to those found
in the all-patients cohort were seen when univariate
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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regression analyses were performed on the cohort of
early-start IFN b-1a patients (data not shown).
Original randomised IFN b-1a dose (44 or 22 mg sc
tiw) was not associated with any long-term clinical
outcome measured from baseline and/or month 24
to LTFU.
Multivariate predictors for LTFU outcomes
When variables reaching p 0.15 in univariate ana-
lyses were included in multivariate models, the pre-
dictive value for LTFU outcomes varied (Table 2).
A consistent association with six or more of the clin-
ical disability outcomes measured from baseline
to LTFU (Table 2) and from month 24 to LTFU
(Table 3) was found for: EDSS score at baseline,
change in EDSS score from baseline to month 24,
baseline brain volume, and MPR. Higher brain
volume at baseline and greater MPR were associated
with better long-term clinical outcomes (including
less likelihood of conversion to SPMS), while
higher baseline EDSS score and greater increase in
EDSS score during the first 24 months were asso-
ciated with worse long-term clinical outcomes.
Associated with some (2), but not all, disability
outcomes measured from baseline to LTFU were:
T2 composite score at month 12, ARR during the
first 24 months, and EDSS progression in the first
24 months.
In the multivariate models, baseline EDSS score,
EDSS progression in the first 24 months, T2 com-
posite score at month 24 LOCF, and baseline log(T2
BOD) were associated with percentage change in
brain volume from baseline to LTFU in the all-
patients cohort. Baseline EDSS score and T2 com-
posite score at month 24 LOCF were also associated
Table 1. Baseline characteristics and long-term outcomes in all patients and in early-start IFN b-1a patients.
Variable
All patients
(n¼ 382)
Early-start IFN
b-1a patients
(n¼ 259)
Baseline and prestudy characteristics
Age (years) at baseline, mean (SD) 35.35 (7.46) 35.30 (7.34)
Women, % 72.5 69.9
Duration (years) of MS at baseline, mean (SD) 7.35 (5.81) 7.97 (6.14)
24-month prestudy ARR, mean (SD) 1.44 (0.52) 1.42 (0.49)
EDSS score at baseline, mean (SD) 2.43 (1.21) 2.43 (1.22)
log(T2 BOD) at baseline, mean (SD) 7.03 (1.30) 7.01 (1.31)
Brain volume (mm3) at baseline, mean (SD) 79.35 (3.94) 79.21 (3.98)
Clinical outcomes at LTFU
Change in EDSS score, mean (SD) þ1.07 (1.67) þ1.08 (1.65)
EDSS progression, % 60.7 60.2
Time (years) to EDSS progression, mediana 5.80 6.54
EDSS score 6, % 22.8 23.9
Time (years) to EDSS score 6, mediana NAb NAb
Conversion to SPMS, % 19.9 20.1
Time (years) to SPMS, mediana NAb NAb
NDO, % 26.4 27.0
Time (years) to NDO, mediana NAb NAb
MRI outcomes at LTFU
Change in log(T2 BOD), mean (SD) þ0.23 (0.52) þ0.21 (0.53)
Change (%) in brain volume, mean (SD) 4.39 (3.01) 4.31 (2.98)
Indicators of treatment exposure
Medication possession ratio (%), mean (SD) 77.97 (26.65) 87.25 (23.12)
Medication possession ratio (%), median 85.61 99.42
ARR: annualised relapse rate; BOD: burden of disease; EDSS: Expanded Disability Status Scale; IFN: interferon;
LTFU: long-term follow-up; MS: multiple sclerosis; NA: not applicable; NDO: negative disability outcome;
SPMS: secondary progressive multiple sclerosis.
aKaplan-Meier estimates.
bMedian not reached, therefore not applicable because of censoring rate of >50%.
Traboulsee et al.
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Table 2. Coefficients for explanatory variables that were found to be prognostic factors (p 0.15) in the final predictive
multivariate regression models for long-term clinical outcomes: baseline to LTFU, all patients.
Prognostic factor for long-term clinical outcome
Variable
Change in
EDSS score
EDSS
prog.
Time to
EDSS prog.
EDSS
score 6
Time to
EDSS
score 6
SPMS Time to
SPMS
NDO Time to
NDO
Baseline/prestudy variables
Prestudy ARR   þ0.2358      
EDSS score
at baseline
   þ1.4125 þ1.2795 þ0.8694 þ0.6304 þ1.2814 þ1.0979
Brain volume
at baseline
0.0552 0.1245 0.0514 0.1326 0.0970 0.0833 0.0614 0.0871 0.0742
Indicators of early clinical activity
ARR from baseline
to month 24
 þ0.2640       
EDSS progression
in first 24 months
þ0.3550    þ0.5027   þ1.1660 þ0.7262
Change in EDSS
score from baseline
to month 24
þ0.6600 þ1.4095 þ0.7770 þ1.0363 þ0.8996 þ0.6781 þ0.5986 þ0.5906 þ0.7181
Indicators of early MRI activity
T2 composite
score at
month 12
þ0.2011   þ0.3360     
Indicators of IFN -1a treatment exposure
MPR     0.0078 0.0093 0.0073  0.0065
ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale; IFN: interferon; LTFU: long-term follow-up; MPR: medication
possession ratio; MRI: magnetic resonance imaging; NDO: negative disability outcome; prog.: progression; SPMS: secondary progressive
multiple sclerosis.
Table 3. Coefficients for explanatory variables that were found to be prognostic factors (p 0.15) in the final predictive
multivariate regression models for long-term clinical outcomes: month 24 to LTFU, all patients.
Prognostic factor for long-term clinical outcome
Variable
Change in
EDSS score
EDSS
prog.
Time to
EDSS prog.
EDSS
score 6
Time to
EDSS
score 6 SPMS
Time to
SPMS NDO
Time to
NDO
Baseline/prestudy variables
Age  þ0.0231 þ0.0153      
EDSS score
at baseline
   þ1.1775 þ1.0862 þ0.8634 þ0.6477 þ1.0564 þ0.9218
Brain volume
at baseline
0.0541 0.1073 0.0612 0.1228 0.1068 0.0779 0.0602 0.0726 0.0758
Indicators of early clinical activity
Change in EDSS
score from baseline
to month 24
0.2386 0.1073 0.1723 þ0.7916 þ0.7080 þ0.6615 þ0.5997 þ0.6465 þ0.6068
Indicators of early MRI activity
T2 composite
score at month 12
þ0.2328        
Indicators of IFN -1a treatment exposure
IFN b-1a start
status: delayed start
0.2317   1.0409 0.8929   0.7221 0.6745
EDSS: Expanded Disability Status Scale; IFN: interferon; LTFU: long-term follow-up; MPR: medication possession ratio; NDO: negative
disability outcome; prog.: progression; SPMS: secondary progressive multiple sclerosis.
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with this MRI outcome in early-start patients, as was
prestudy ARR.
The R2 coefficient of determination for the final
model predicting change in EDSS score from base-
line to LTFU was 0.35 for all patients and 0.31 for
the early-start cohort.
Discussion
Disease course, MRI findings, and treatment
response are highly heterogeneous among patients
with MS, especially over time. Identifying factors
that are prognostic for long-term disability outcomes
could therefore be useful in identifying patients at
high risk of disability progression, and help deter-
mine appropriate long-term treatment. Due to the
heterogeneity of MS, large and robust long-term
data sets are required to identify factors that may
be prognostic. The PRISMS LTFU population pro-
vides one of the most complete data sets of its type,
with data available up to eight years after study ini-
tiation. Participating centres had a high average
retention rate (77%) and 72% of patients returning
for the LTFU visit were still receiving sc IFN b-1a.
In addition, assessment and MRI protocols for the
LTFU visit were consistent with those used through-
out the study.
Patients enrolled in the PRISMS study represented a
relatively homogeneous population (83% had an
EDSS score 3.5) and whilst this may have limited
generalisability to other clinical settings it may have
helped to minimise confounding of the analysis of
prognostic variables. After eight years, the levels of
disability and disability progression were much more
heterogeneous, making this a valuable cohort in
which to explore early predictors of relatively
long-term clinical outcomes. There is a possibility
of selection bias among the patients who returned
for the LTFU visit, as patients with better disease
outcomes at seven to eight years may have been
more willing or able to participate.
The analysis was performed in all patients who had
returned for the LTFU visit and also in patients from
the early-start sc IFN b-1a cohort only. Separate ana-
lysis of the early-start cohort patients allowed evalu-
ation of whether earlier initiation of treatment
impacts the predictive value of early variables, espe-
cially those referring to changes in MRI and relapse
rate during the first two years.
IFN b-1a start status (early or delayed) was not a
significant univariate predictor for any clinical out-
comes measured during the eight-year follow-up.
However, in such an intention-to-treat analysis, not
all early-start patients had a longer duration of active
treatment over the follow-up period. MPR, a meas-
ure of time on therapy during the eight-year follow-
up, was identified as a predictor of clinical outcome
in the final multivariate regression models, favouring
patients with the highest MPR. Notably, the coeffi-
cients calculated for MPR were very small. This is
consistent with the high adherence rates observed
(mean MPR overall, 78%; for early-starters, 87%).
Previous data suggest a potential worsening of
relapse rates at lower adherence rates, with relapse
rates tending to remain low in patients with higher
adherence (objective adherence up to 75% or MPR
up to 70%).7,8 A recent 15-year follow-up of patients
with RRMS indicating that higher levels of cumula-
tive dose exposure and longer time on sc IFN b-1a
treatment were associated with better clinical out-
comes, further highlights the potential benefits of
a longer duration of MS therapy.9
Multivariate analysis identified the following vari-
ables to be predictors of long-term disability: age,
EDSS score and brain volume at baseline, early
change in EDSS and MPR. Markers of inflammatory
activity from baseline to month 24 included ARR
and the T2 composite score. Analysis of the early-
start cohort patients provided similar results to the
analysis of all patients. Baseline brain volume, base-
line EDSS and early change in EDSS were the most
frequently identified predictors of the various long-
term disability outcomes. Assessing a patient’s base-
line brain volume and early disability status may
therefore be important in therapeutic decision
making.
The prognostic value of EDSS observed in the cur-
rent study is supported by a number of other studies
that previously identified baseline EDSS or early
change in EDSS as predictive of long-term disability
or cognitive outcomes in MS patients.1012 MRI at
baseline, in terms of brain volume and lesion burden,
have also been found to correlate with disability out-
comes.11,13 Other prognostic factors previously iden-
tified include age older than 25 years at onset,
clinical course during the first two years of disease,
and involvement of the pyramidal system at onset.10
In a long-term trial of patients on IFNb-1b, measure-
ments at baseline were observed to have a greater
prognostic value than on-study measurements, which
were found to contribute little to the variance in
long-term outcomes.11
In the current study, all identified predictors taken
together accounted for only approximately one-third
Traboulsee et al.
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of the variability in long-term disability outcome,
suggesting that other unidentified factors must play
important roles. Similarly, models developed previ-
ously accounted for approximately half of the vari-
ance in long-term outcomes.11 In addition, it is
possible that the predictive value of the EDSS-
related explanatory variables could have been
affected by the known low sensitivity and low
inter-rater reliability of the EDSS.14,15
Although it is widely considered that poor adherence
to treatment can adversely affect disease outcomes in
patients with MS,8,1618 to date few studies have
examined this association. Post hoc analyses (separ-
ate to the current analysis) of clinical and MRI out-
comes in the PRISMS LTFU cohort according to
exposure to IFN b-1a treatment (cumulative dose
of IFN b-1a, cumulative time on treatment, and con-
tinuous vs non-continuous treatment) have also sug-
gested that better adherence leads to better
outcomes.15
In summary, in clinical practice we are still in need
of more accurate factors that can predict a successful
or poor outcome at up to eight years after starting
therapy. In this post hoc analysis of the PRISMS
LTFU cohort, higher baseline brain volume pre-
dicted better long-term clinical outcomes, while
larger increases in EDSS score during the first 24
months predicted worse outcomes. A measure of
time on therapy, MPR, was also identified as a pre-
dictor for many long-term clinical outcomes, with a
longer duration of IFN b-1a treatment associated
with better outcomes. Relapse rate and changes in
MRI disease measures in the first two years of treat-
ment were also predictors of long-term outcomes,
but not as consistently so as change in EDSS score
over a similar interval.
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